| 英語論文 |
| |
1 |
Kenmotsu H, Sugawara S, Watanabe Y, Saito H, Okada M, Chen-Yoshikawa TF, Ohe Y, Nishio W, Nakagawa S, Nagao H.Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).Cancer Sci. 2022;113(12):4327-4338. |
| |
2 |
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T.Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.J Thorac Oncol. 2022;17(9):1098-1108. |
| |
3 |
Kenmotsu H, Imamura CK, Kawamura T, Oyakawa T, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Yamamoto N, Takahashi T, Tanigawara Y.Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.Cancer Chemother Pharmacol. 2022;90(2):115-123. |
| |
4 |
Kenmotsu H, Mori K, Mizuno R, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T.Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.Lung Cancer. 2022;164:39-45. doi: 10.1016/j.lungcan. |
| |
5 |
Naito T, Uchino J, Kojima T, Matano Y, Minato K, Tanaka K, Mizukami T, Atagi S, Higashiguchi T, Muro K, Takayama K, Furuse J, Morishima E, Takiguchi T, Tamura K.A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.Cancer. 2022;128(10):2025-2035. |
| |
6 |
Doshita K, Tabuchi Y, Kenmotsu H, Omori S, Kawabata T, Kodama H, Nishioka N, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Kaneko T, Takahashi T.Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy.Adv Radiat Oncol. 2022;8(2):101129. |
| |
7 |
Omori S, Muramatsu K, Kawata T, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Sugino T, Takahashi T.Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.J Cancer Res Clin Oncol. 2022;148(9):2455-2463. |
| |
8 |
Aso S, Kawamura N, Yanagida H, Nakajima K, Ishikawa H, Omori S, Murakami H, Takahashi T, Naito T.Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study.Asia Pac J Oncol Nurs. 2022;9(8):100076. |
| |
9 |
Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T.Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.Thorac Cancer. 2022;13(14):2064-2074. |
| |
10 |
Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T.Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.Thorac Cancer. 2022;13(10):1496-1504. |
| |
11 |
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T.Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.Invest New Drugs. 2022;40(2):464. |
| |
12 |
Doshita K, Kenmotsu H, Omori S, Tabuchi Y, Kawabata T, Kodama H, Nishioka N, Miyawaki E, Iida Y, Miyawaki T, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Kaneko T, Takahashi T.Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.Invest New Drugs. 2022;40(2):411-419. |
| |
13 |
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T.Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.Invest New Drugs. 2022;40(2):403-410. |
| |
14 |
Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Takahashi K, Takahashi T.Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.Support Care Cancer. 2022;30(2):1633-1641. |
| |
15 |
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.Invest New Drugs. 2022;40(1):106-114. |
| |
16 |
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M.Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.Cancer Sci. 2022;113(1):287-296. |
| |
17 |
Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H.Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.BMC Cancer. 2022;22(1):342. |
